You are here: Industry Insights > Bridge Biotherapeutics

News List

Bridge Biotherapeutics Announces Initiation of the Phase I Clinical Trial for BBT-401 in China prnasia
October 20, 2021
Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company focused on developing novel drugs for inflammation, fibrosis and oncology, announced that the first subject has been dosed in the China Phase I clinical trial of BBT-401...
Bridge Biotherapeutics terminates collaboration agreement with Boehringer pharmaceutical-technology
November 11, 2020
Bridge Biotherapeutics and Boehringer Ingelheim have mutually agreed to terminate their previously signed collaboration and licence agreement to develop BBT-877.
Bridge Biotherapeutics, Boehringer Ingelheim cancel agreement to develop BBT-877 for idiopathic pulmonary fibrosis expresspharma
November 10, 2020
Under the License Agreement, Bridge Biotherapeutics will regain all rights to BBT-877.
Bridge Biotherapeutics Announces China NMPA Clearance of IND for BBT-401, a Pellino-1 Inhibitor for UC prnasia
January 05, 2020
Bridge Biotherapeutics plans to initiate a Phase I study of BBT-401 in Chinese subjects in May 2020. The safety, tolerability and pharmacokinetic data of the drug candidate will be assessed with single and multiple ascending oral doses in the study.
Boehringer forms alliance with Bridge Biotherapeutics for IPF drug pharmaceutical-technology
July 22, 2019
Boehringer Ingelheim has entered a collaboration and licence agreement to develop South Korea-based Bridge Biotherapeutics’ drug candidate for fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF).
Bridge Biotherapeutics becomes new resident at JLABS biospectrumasia
July 04, 2019
Becomes a resident company of the newly opened incubation center for life science and biotechnology in the Asia-Pacific region
Bridge Biotherapeutics Signs US$40M License Agreement with Daewoong Pharmaceutical for Co-development of UC Drug Candidate pharmafocusasia
December 19, 2018
Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea, announced that the company signed a license agreement with ....